IN2014MN01876A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01876A IN2014MN01876A IN1876MUN2014A IN2014MN01876A IN 2014MN01876 A IN2014MN01876 A IN 2014MN01876A IN 1876MUN2014 A IN1876MUN2014 A IN 1876MUN2014A IN 2014MN01876 A IN2014MN01876 A IN 2014MN01876A
- Authority
- IN
- India
- Prior art keywords
- baff
- bispecific antibodies
- sle
- pss
- psoriasis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Bispecific antibodies are provided that specifically bind B cell Activating Factor of the TNF Family (BAFF) and Interleukin 17A (IL 17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL 17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN) Systemic Lupus Erythematosus (SLE) Rheumatoid Arthritis (RA) Psoriasis (Ps) Ankylosing Spondylitis (AS) Psoriatic Arthritis (PA) primary Sjögren s Syndrome (pSS) or Multiple Myeloma (MM).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636302P | 2012-04-20 | 2012-04-20 | |
| US201361768747P | 2013-02-25 | 2013-02-25 | |
| PCT/US2013/036677 WO2013158577A1 (en) | 2012-04-20 | 2013-04-16 | Anti-baff-anti-il-17 bispecific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01876A true IN2014MN01876A (en) | 2015-07-03 |
Family
ID=48539373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1876MUN2014 IN2014MN01876A (en) | 2012-04-20 | 2013-04-16 |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9359448B2 (en) |
| EP (2) | EP2838920B1 (en) |
| JP (1) | JP6216772B2 (en) |
| KR (1) | KR101673735B1 (en) |
| CN (1) | CN104220455B (en) |
| AP (1) | AP2014008002A0 (en) |
| AR (1) | AR090626A1 (en) |
| AU (1) | AU2013249546B2 (en) |
| BR (1) | BR112014025649A2 (en) |
| CA (1) | CA2869148C (en) |
| CL (1) | CL2014002616A1 (en) |
| CO (1) | CO7160039A2 (en) |
| CR (1) | CR20140466A (en) |
| CY (1) | CY1118824T1 (en) |
| DK (1) | DK2838920T3 (en) |
| DO (1) | DOP2014000234A (en) |
| EA (1) | EA029185B1 (en) |
| EC (1) | ECSP14023405A (en) |
| ES (2) | ES2621917T3 (en) |
| GT (1) | GT201400217A (en) |
| HK (1) | HK1201862A1 (en) |
| HR (1) | HRP20170468T1 (en) |
| HU (1) | HUE032153T2 (en) |
| IL (1) | IL234965B (en) |
| IN (1) | IN2014MN01876A (en) |
| LT (1) | LT2838920T (en) |
| ME (1) | ME02596B (en) |
| MX (1) | MX367460B (en) |
| MY (1) | MY173282A (en) |
| NZ (1) | NZ630865A (en) |
| PE (1) | PE20142147A1 (en) |
| PH (1) | PH12014502333A1 (en) |
| PL (1) | PL2838920T3 (en) |
| PT (1) | PT2838920T (en) |
| RS (1) | RS55729B1 (en) |
| SG (1) | SG11201406726PA (en) |
| SI (1) | SI2838920T1 (en) |
| TW (1) | TWI585103B (en) |
| WO (1) | WO2013158577A1 (en) |
| ZA (1) | ZA201407272B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2012149227A (en) | 2010-05-20 | 2014-06-27 | Аблинкс Нв | BIOLOGICAL MATERIALS RELATING TO HER3 |
| UA117218C2 (en) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
| AR090626A1 (en) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | ANTI-BAFF-ANTI-IL-17 BIESPECIFIC ANTIBODIES |
| TW201444867A (en) * | 2013-03-08 | 2014-12-01 | Lilly Co Eli | Anti-TNF-anti-IL-17 bispecific antibodies |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| JOP20140087B1 (en) | 2013-03-13 | 2021-08-17 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| CA2929846C (en) * | 2013-11-19 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| WO2016039801A1 (en) | 2014-01-31 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Novel anti-baff antibodies |
| AR102417A1 (en) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | ANTI-TNF- / ANTI-IL-23 BIESPECTIFIC ANTIBODIES |
| TW202144411A (en) * | 2015-07-23 | 2021-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof |
| CN105061596B (en) * | 2015-08-05 | 2019-01-29 | 江苏诺迈博生物医药科技有限公司 | The monoclonal antibody and its application of human B lymphocyte stimulating factor |
| US20200385478A1 (en) * | 2018-01-05 | 2020-12-10 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
| CN117529506A (en) * | 2021-06-11 | 2024-02-06 | 海南先声药业有限公司 | Bifunctional fusion protein molecules of anti-human IL-17 antibodies and TACI |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| AR035119A1 (en) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | ANTI-HTNFSF13B HUMAN ANTI-BODIES |
| RU2515108C2 (en) * | 2005-08-19 | 2014-05-10 | Эббви Инк | Immunoglobulin with double variable domains and its applications |
| KR101158959B1 (en) | 2005-12-13 | 2012-07-09 | 일라이 릴리 앤드 캄파니 | Anti-il-17 antibodies |
| US20110293629A1 (en) * | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
| AR090626A1 (en) * | 2012-04-20 | 2014-11-26 | Lilly Co Eli | ANTI-BAFF-ANTI-IL-17 BIESPECIFIC ANTIBODIES |
-
2013
- 2013-04-08 AR ARP130101134A patent/AR090626A1/en active IP Right Grant
- 2013-04-12 TW TW102113167A patent/TWI585103B/en not_active IP Right Cessation
- 2013-04-16 DK DK13726321.6T patent/DK2838920T3/en active
- 2013-04-16 PL PL13726321T patent/PL2838920T3/en unknown
- 2013-04-16 RS RS20170160A patent/RS55729B1/en unknown
- 2013-04-16 EP EP13726321.6A patent/EP2838920B1/en active Active
- 2013-04-16 JP JP2015507095A patent/JP6216772B2/en active Active
- 2013-04-16 BR BR112014025649A patent/BR112014025649A2/en not_active Application Discontinuation
- 2013-04-16 EA EA201491622A patent/EA029185B1/en not_active IP Right Cessation
- 2013-04-16 LT LTEP13726321.6T patent/LT2838920T/en unknown
- 2013-04-16 SG SG11201406726PA patent/SG11201406726PA/en unknown
- 2013-04-16 HU HUE13726321A patent/HUE032153T2/en unknown
- 2013-04-16 NZ NZ630865A patent/NZ630865A/en not_active IP Right Cessation
- 2013-04-16 ES ES13726321.6T patent/ES2621917T3/en active Active
- 2013-04-16 IN IN1876MUN2014 patent/IN2014MN01876A/en unknown
- 2013-04-16 AP AP2014008002A patent/AP2014008002A0/en unknown
- 2013-04-16 US US13/863,544 patent/US9359448B2/en active Active
- 2013-04-16 KR KR1020147028867A patent/KR101673735B1/en active IP Right Grant
- 2013-04-16 ES ES17153380T patent/ES2789474T3/en active Active
- 2013-04-16 PT PT137263216T patent/PT2838920T/en unknown
- 2013-04-16 CA CA2869148A patent/CA2869148C/en active Active
- 2013-04-16 EP EP17153380.5A patent/EP3192809B1/en active Active
- 2013-04-16 ME MEP-2017-41A patent/ME02596B/en unknown
- 2013-04-16 PE PE2014001619A patent/PE20142147A1/en active IP Right Grant
- 2013-04-16 CN CN201380020761.7A patent/CN104220455B/en active Active
- 2013-04-16 MY MYPI2014703075A patent/MY173282A/en unknown
- 2013-04-16 AU AU2013249546A patent/AU2013249546B2/en not_active Ceased
- 2013-04-16 WO PCT/US2013/036677 patent/WO2013158577A1/en active Application Filing
- 2013-04-16 MX MX2014012692A patent/MX367460B/en active IP Right Grant
- 2013-04-16 SI SI201330522A patent/SI2838920T1/en unknown
-
2014
- 2014-09-30 CL CL2014002616A patent/CL2014002616A1/en unknown
- 2014-10-02 IL IL234965A patent/IL234965B/en active IP Right Grant
- 2014-10-06 CR CR20140466A patent/CR20140466A/en unknown
- 2014-10-07 ZA ZA2014/07272A patent/ZA201407272B/en unknown
- 2014-10-15 GT GT201400217A patent/GT201400217A/en unknown
- 2014-10-16 DO DO2014000234A patent/DOP2014000234A/en unknown
- 2014-10-17 EC ECIEPI201423405A patent/ECSP14023405A/en unknown
- 2014-10-17 PH PH12014502333A patent/PH12014502333A1/en unknown
- 2014-10-20 CO CO14231938A patent/CO7160039A2/en unknown
-
2015
- 2015-03-12 HK HK15102524.4A patent/HK1201862A1/en not_active IP Right Cessation
-
2016
- 2016-05-18 US US15/157,782 patent/US9708402B2/en active Active
-
2017
- 2017-03-21 HR HRP20170468TT patent/HRP20170468T1/en unknown
- 2017-03-27 CY CY20171100380T patent/CY1118824T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01876A (en) | ||
| MX2015011957A (en) | Anti-tnf-anti-il-17 bispecific antibodies. | |
| AU2018253639A1 (en) | Compositions and methods for antibodies targeting EPO | |
| NZ711355A (en) | Anti-lag-3 binding proteins | |
| SG10201906328RA (en) | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) | |
| EP4071176A3 (en) | Agonistic tnf receptor binding agents | |
| CL2008001673A1 (en) | Simple variable domain of anti-interleukin 1 (il-1r1) type 1 immunoglobulin; nucleic acid encoding it; vector and host cell; Method of production; il-1r1 antagonist comprising it; composition comprising the antagonist; and use of the antagonist to treat an inflammatory condition. | |
| UA117575C2 (en) | ANTIBODY WHICH SPECIFICALLY Binds to IL-17A AND ITS APPLICATION | |
| PH12015501994A1 (en) | Antibodies that bind il-23 | |
| CL2007002835A1 (en) | SPECIFIC MONOCLONAL ANTIBODY FOR THE CXCR4 RECEIVER; NUCLEIC ACID THAT CODIFIES IT; VECTOR AND CELL THAT UNDERSTAND IT; METHOD OF PRODUCTION; IMMUNOCONJUGADO AND COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT CANCER, INFLAMMATORY DISORDERS AND | |
| EP4036240A3 (en) | Transduction buffer | |
| NZ708033A (en) | Anti-blood dendritic cell antigen 2 antibodies and uses thereof | |
| EA201391298A1 (en) | NONWATER CONCENTRATED SUSPENSION COMPOSITIONS WITH REDUCED VISCOSITY BASED ON ANTIBODIES | |
| PH12014501410A1 (en) | Compositions and methods for antibodies targeting factor p | |
| MX353476B (en) | Anti-cxcl13 antibodies and methods of using the same. | |
| CL2008000820A1 (en) | ISOLATED ANTIBODY OR FUNCTIONAL FRAGMENTS WITH CAPACITY TO NEUTRALIZE HIV BIND; NUCLEIC ACID THAT CODIFIES IT; VECTOR AND CELL GUEST THAT UNDERSTAND SUCH NUCLEIC ACID; METHOD FOR PRODUCING AN ANTIBODY; USE OF THE ANTIBODY FOR THE TREATMENT | |
| MX2013013832A (en) | Fc RECEPTOR BINDING PROTEINS. | |
| MX2016006101A (en) | Il-17a conjugate and uses thereof. | |
| MY158481A (en) | Compositions and methods for treating inflammatory disorders | |
| MX371412B (en) | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma. | |
| EA201491471A1 (en) | COMPOSITION CONTAINING ANTIBODY AGAINST IL-17 | |
| TN2014000413A1 (en) | Anti-baff-anti-il-17 bispecific antibodies | |
| WO2014113431A3 (en) | Methods and compositions for targeting immunoglobulins | |
| TH1401006266A (en) | ANTI-BAFF-ANTI-IL-17 Bspecific Antibody | |
| UA113080C2 (en) | A SPECIFIC ANTIBODY THAT SPECIFICALLY Binds to IL17 AND BAFF |